Physician profile
John C Lasiter
NPI 1891899076
$741.18
in general payments reported to CMS, 2019-2025
11 companies · $88.32 in 2025
The $88.32 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.56 · 2021: $22.95 · 2022: $68.50 · 2023: $297 · 2024: $226 · 2025: $88.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $282.87 | 2022-2024 | Trudi Nav Cable, Relieva Spinplus |
| Stryker Corporation | $108.26 | 2020-2023 | Xpress Ent Dilation System |
| Inspire Medical Systems, INC. | $100.58 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $66.83 | 2022-2025 | Nucala |
| Integra Lifesciences Corporation | $47.12 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Regeneron Healthcare Solutions, INC. | $28.02 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $26.50 | 2024 | Cuvitru |
| Optinose US, INC. | $22.95 | 2021 | |
| Smith+Nephew, INC. | $19.75 | 2024 | Tula |
| Genzyme Corporation | $19.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.85 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lasiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.